The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, introduces a novel clonotypic mass spectrometry assay (EasyM) to predict outcomes following autologous stem cell transplantation (autoSCT) in multiple myeloma (MM). This assay successfully predicts progression-free survival (PFS) by quantifying measurable residual disease (MRD) in peripheral blood following autoSCT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Takeda, Janssen, Pfizer, Karyopharm, Harpoon, Legend, Sanofi, Bristol Myers Squibb
Research Funding: Takeda, Sanofi, Bristol Myers Squibb
